LENZ Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences:

GlobeNewsWire • May 26, 2026

LENZ Therapeutics Q1 Earnings Call Highlights

LENZ Therapeutics NASDAQ: LENZ reported first-quarter 2026 results that showed continued prescription growth for its presbyopia eye drop VIZZ, while management acknowledged that new patient adoption and routine prescribing by eye care professionals are developing more gradually than expected.

MarketBeat • May 12, 2026

LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call Transcript

LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 12, 2026

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ® product sales Approximately 46,000 paid prescriptions filled and over 10,000 prescribing eye care professionals from launch through Q1 2026 Together with Sarah Jessica Parker, launched the DTC campaign in Q1 2026 Expanded sales force on-track to be fully deployed by the end of Q2 2026 Management to host conference call today, May 11, 2026, at 4:30 p.m. EDT SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today reported financial results for the first quarter ended March 31, 2026 and recent corporate highlights.

GlobeNewsWire • May 11, 2026

LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates

LENZ Therapeutics, Inc. (LENZ) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $0.53 per share a year ago.

Zacks Investment Research • May 11, 2026

LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Monday, May 11, 2026, at 4:30 p.m. EDT to report its first quarter 2026 financial results and recent corporate highlights.

GlobeNewsWire • May 4, 2026

LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom

MHRA submission follows EMA validation of the VIZZ MAA in March 2026 Sixth ex-U.S. regulatory submission for VIZZ underscores accelerating global expansion SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) today announced that it has submitted a Marketing Authorization Application (MAA) to the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for the review and approval of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia in adults. Since receiving U.S. Food and Drug Administration (FDA) approval in July 2025, LENZ has moved rapidly to expand global access to VIZZ, with submission of the MAA in the United Kingdom representing the sixth ex-U.S. regulatory submission for VIZZ.

GlobeNewsWire • Apr 20, 2026

LENZ Therapeutics: Speculative But Strong Buy

LENZ Therapeutics offers a very high-risk but even higher-reward opportunity with Vizz, its aceclidine-based eye drop for presbyopia. I estimate a bit conservative base-case fair value of $25 per share, implying ~200% upside from current levels, driven by US and international partnerships. Key forward driver is Vizz refill rates, with management set to disclose actual refill percentages in H2; side effect fears remain demand headwinds.

Seeking Alpha • Apr 1, 2026

Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week

It's recently commercialized VIZZ hasn't generated much fizz with the market yet. It has high hopes for the blurry vision treatment.

The Motley Fool • Mar 27, 2026

Why Lenz Therapeutics Stock Crashed Today

Lenz missed on sales and missed on Q4 earnings this morning. The vision drugs company said it's on pace to hit 45,000 prescriptions for VIZZ by the end of Q1.

The Motley Fool • Mar 24, 2026